Study ID: ECOG 1Z11
A cohort study to evaluate genetic predictors for aromatase inhibitor musculoskeletal symptoms
Medications such as anastrozole, which are classified as aromatase inhibitors (AI), are important parts of therapy for hormone receptor-positive breast cancer patients. But with their more widespread use, a syndrome called Aromatase Inhibitor Musculoskeletal Syndrome (AIMS) that is related to these agents has emerged.
This study of post-menopausal women of Asian descent who have been diagnosed with either stage 1, 2 or 3 hormone receptor-positive breast cancer is to determine genetic predictors of AIMS. All patients will be given anastrozole orally once daily for 12 months. Patients who previously had been treated with tamoxifen are permitted. Patients will be asked to complete questionnaires, and blood samples will be drawn.
This study is for post-menopausal women of Asian descent ER and/or PR positive stage I-III adenocarcinoma. They will be treated with anastrazole, 1 mg orally, for 12 months. Use of prior tamoxifen allowed, but use of LHRH agonists is not permitted. Blood samples will be drawn, and questionnaires given to patients. Patients must have adequate hepatic, hematologic, and renal functioning to be able to be administered anastrozole.
- Must have completed chemotherapy for estrogen and/or progesterone receptor-positive Stage 1–3 breast cancer
- Must not have received prior AI therapy
- Must have no chronic conditions or prior history of deep vein thrombosis or pulmonary embolism